Medication Optimization Using Pharmacogenomic Testing in a Complex Mental Health Population Prescribed Psychiatric...

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Psychiatric Pharmacy

Background:

• Polypharmacy is increasingly common, raising risks of drug interactions and adverse drug reactions.
• Pharmacogenomic (PGx) assays predict individual medication responses based on genetic markers.
• Optimizing medication regimens for polypharmacy patients is a significant clinical challenge.

Purpose of the Study:

• To examine the impact of PGx results on clinical management of Veterans prescribed psychiatric polypharmacy.
• To assess the utility of PGx assays in guiding medication adjustments for complex patient populations.
• To evaluate the effect of PGx-guided interventions on clinical outcomes and adverse drug effects.

Main Methods:

• A 12-week pilot study involving 53 Veteran outpatients on polypharmacy (mean 13.15 medications).
• Psychiatric medication providers accessed PGx assay results and an algorithm decision tool for drug-drug-gene interactions.
• Medication management decisions were informed by PGx data, with providers changing original plans in 83% of cases.

Main Results:

• Clinical improvement observed in depression (P=.01) and mental health quality of life (P<.05) over 12 weeks.
• Adverse drug effects remained unchanged or improved.
• Polypharmacy rates were unchanged, but medication regimens were adjusted based on PGx findings.

Conclusions:

• Medication changes guided by PGx assays may benefit Veterans with psychiatric polypharmacy.
• PGx testing can facilitate personalized medication management in complex patient populations.
• The study suggests PGx assays are a valuable tool for optimizing polypharmacy treatment.